Anteris Technologies implanted its proprietary DurAVRTM Transcatheter Heart Valve into the first three animals (pigs) as part of a transcatheter aortic valve replacement (TAVR) study. This first feasibility study in pigs aims to confirm DurAVRTM valve deployment and fixation (anchoring) as well as providing insight into the valve's haemodynamic function. The study of nine animals is being conducted in Minneapolis, USA and is scheduled to be completed by 31 December 2020. The three pigs were implanted with a 25mm valve via a catheter by a trans-apical approach. The Effective Orifice Areas (EOA) were 2.45cm2 on initial readings, consistent with the positive results observed in patients surgically implanted in the first-in-human SAVR clinical study and in previous animal and laboratory studies of the DurAVRTM valve. The EOA, a measurement of haemodynamic function, is a significant indicator of valve function and performance. Additionally, the study replicated the findings of the 3D single-piece DurAVRTM aortic valve as shown in the surgical aortic valve replacement (SAVR) animal study and, thus far, in the first-in-human SAVR clinical study of the DurAVRTM valve underway at the University Hospitals, Leuven in Belgium. This early feasibility study is critical as the company move toward the next phase of development. The lessons learned in this study will allow the company to make refinements to the frame and delivery system for the DurAVRTM aortic valve, which ultimately will be applied to the device used in its planned US FDA submission for a human clinical trial in 2021.